Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15865607 | 0.88 | NPSR1 (0.51) | NPSR1BRD4ALDH1A1P2RX7KDM4E | |
| SCHEMBL12453798 | 0.86 | KDM4E (0.55) | NPSR1BRD4KDM4ELMNAALOX15 | |
| SCHEMBL6793428 | 0.84 | NPSR1 (0.77) | NPSR1BRD4ALDH1A1KDM4ELMNA | |
| SCHEMBL16866486 | 0.83 | ADORA2A (0.52) | NPSR1BRD4ADORA2ACYP1A2PARP1 | |
| SCHEMBL28615284 | 0.81 | NPSR1 (0.49) | NPSR1BRD4ALDH1A1P2RX7KDM4E | |
| SCHEMBL9298408 | 0.80 | NPSR1 (0.56) | NPSR1BRD4KDM4ELMNAADORA2A | |
| SCHEMBL1054149 | 0.79 | NPSR1 (0.44) | NPSR1BRD4ALDH1A1P2RX7KDM4E | |
| SCHEMBL30952862 | 0.79 | NPSR1 (0.44) | NPSR1BRD4ALDH1A1P2RX7KDM4E | |
| SCHEMBL12432224 | 0.79 | IRAK4 (0.49) | NPSR1BRD4ALDH1A1P2RX7KDM4E | |
| SCHEMBL26029689 | 0.79 | KDM4E (0.47) | NPSR1BRD4KDM4ELMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1921077-B1 | AGENT FOR TREATING AND/OR PREVENTING SLEEP DISORDER | KYOWA HAKKO KIRIN CO LTD (JP) | 2017-07-26 | — | — | EP | disclosed |
| US-8653141-B2 | HIV protease inhibiting compounds | ABBVIE INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2264032-B1 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBVIE INC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| EP-2216334-B1 | HIV protease inhibiting sulfonamides | ABBOTT LAB (US) | 2012-10-31 | — | — | EP | disclosed |
| US-8193227-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110003827-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2011-01-06 | — | — | US | disclosed |
| EP-2264032-A2 | Hiv protease inhibiting sulfonamides | Abbott Laboratories (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-2216334-A1 | Hiv protease inhibiting sulfonamides | Abbott Laboratories (US) | 2010-08-11 | — | — | EP | disclosed |
| EP-1709037-B1 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBOTT LAB (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-1709037-A2 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBOTT LABORATORIES (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005061450-A2 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBOTT LABORATORIES (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050131042-A1 | HIV protease inhibiting compounds | ABBOTT LABORATORIES | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003827-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | NPSR1 4034/4885BRD4 2440/4885ALDH1A1 2920/4885 |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | SERPINB1, HPN, DNPEP | NPSR1 4034/4885BRD4 2440/4885ALDH1A1 2920/4885 |
| US-20050131042-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | NPSR1 4034/4885BRD4 2440/4885ALDH1A1 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.